Skip to main content

Kesimpta

Pronunciation: key-simp-ta
Generic name: ofatumumab
Dosage form: single-dose prefilled Sensoready pen for subcutaneous use (20 mg/0.4 mL), single-dose prefilled syringe for subcutaneous use (20 mg/0.4 mL)
Drug classes: CD20 monoclonal antibodies, Selective immunosuppressants

Medically reviewed by Carmen Pope, BPharm. Last updated on Jun 16, 2025.

What is Kesimpta?

Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is self-administered once a month by subcutaneous injection after an initial dosing period. 

Exactly how Kesimpta works is unknown, but it is thought to involve binding to CD20, a protein present on pre-B and mature B lymphocytes (lymphocytes are a type of white blood cell that are more abundant in people with MS). Once bound to the B-cell, Kesimpta triggers the destruction of the cell. Clinical trials report that Kesimpta slows MS progression and reduces the rate of relapse, but it is not a cure. Kesimpta belongs to the drug class called CD20-directed cytolytic antibodies. It may also be called a selective immunosuppressant.

Kesimpta (ofatumumab) gained FDA approval on October 26, 2009. There is no generic or biosimilar. Kesimpta is not interchangeable with another brand of ofatumumab called Arzerra used for CLL.

Side effects

The most common side effects of Kesimpta are:

Serious side effects and warnings

Kesimpta can cause the following serious side effects:

Tell your healthcare provider right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes during treatment.

These are not all the possible side effects of Kesimpta. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before using Kesimpta

Do not use Kesimpta if you:

Before using this medicine, tell your healthcare provider about all of your medical conditions, including if you:

Pregnancy

It is not known if this medicine will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with this medicine and for 6 months after your last treatment. Talk with your healthcare provider about what birth control method is right for you during this time.

Pregnancy Registry: There is a registry for women who become pregnant during treatment with Kesimpta. If you become pregnant while taking Kesimpta, tell your healthcare provider right away. Talk to your healthcare provider about registering with the MotherToBaby Pregnancy Study in Multiple Sclerosis.

The purpose of the registry is to collect information about your health and your baby’s health. For more
information or to register, contact MotherToBaby by calling 1-877-311-8972, by sending an email to MotherToBaby@health.ucsd.edu, or go to www.mothertobaby.org/join-study.

Breastfeeding

 It is not known if this medicine passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take this medicine.

How should I use Kesimpta?

See the detailed Instructions for Use that come with the Kesimpta Package Insert for information about how to prepare and inject a dose of this medicine and how to properly throw away (dispose of) used Sensoready pens or prefilled syringes.

Dosing information

Dosage of Kesimpta for relapsing forms of Multiple Sclerosis

What happens if I miss a dose?

If you miss a monthly injection, give it as soon as possible without waiting until the next scheduled dose. After that, use your injections a month apart.

What other drugs will affect Kesimpta?

Tell your doctor about all your other medicines, especially drugs that weaken the immune system such as

This list is not complete. Other drugs may affect Kesimpta, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Does Kesimpta interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Storage

Store Kesimpta in a refrigerator between 36°F to 46°F (2°C to 8°C). Keep it in the original carton until ready for use to protect it from light.

If needed, Kesimpta may be stored for up to 7 days at room temperature, up to 86°F (30°C ). Write the date taken out of the refrigerator in the space provided on the carton.

If stored below 86°F (30°C), unused Kesimpta may be returned to the refrigerator and must be used within the next 7 days. If this Kesimpta is not used within those 7 days, then discard the medicine.

Do not freeze. Do not shake.

Keep out of the reach of children.

Ingredients

Active ingredient: ofatumumab
Inactive ingredients (pen and prefilled syringe): arginine, disodium edetate, polysorbate 80, sodium acetate trihydrate, sodium chloride, and Water for Injection. Hydrochloric acid may be added.

Available as:

Manufacturer

Kesimpta is made by Novartis, with its headquarters in Basel, Switzerland.

Kesimpta Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There are 2 for Kesimpta.

Arzerra (ofatumumab) - Novartis Pharmaceuticals Corporation
Formulation type Strength
Single-Dose Vial 1,000 mg/50 mL Discontinued
Single-Dose Vial 100 mg/5 mL Discontinued

View Arzerra information in detail.

Kesimpta (ofatumumab) - Novartis Pharmaceuticals Corporation
Formulation type Strength
Autoinjector 20 mg/0.4 mL
Pre-Filled Syringe 20 mg/0.4 mL Discontinued

Popular FAQ

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis.

Continue reading
Is Kesimpta better than Ocrevus?

In patients with relapsing forms of multiple sclerosis, Kesimpta (ofatumumab) is thought to be more effective than Ocrevus (ocrelizumab) in some ways, but no clinical trials have directly compared the two drugs

Ocrevus is the only one of the two drugs approved to treat primary progressive multiple sclerosis Continue reading

What are 8 key Kesimpta side effects to watch out for?

Kesimpta (ofatumumab) is an FDA-approved anti-CD20 monoclonal antibody used to treat relapsing forms of multiple sclerosis (MS) in adults. Like all medications, there are several side effects you should watch out for and know how to manage. Continue reading

How long can Kesimpta be out of the fridge?

Kesimpta (ofatumumab) can be kept at room temperature for up to 7 days, as long as the temperature doesn’t get higher than 30 degrees C (86 degrees F). Continue reading

How long does it take for Kesimpta to work?

Kesimpta (ofatumumab) starts to work to lower B cells within a week of starting treatment. In studies, Kesimpta reduced the risk of worsening MS at 3 months of treatment. Continue reading

Where and how is Kesimpta injected?

Kesimpta (ofatumumab) is injected under the skin (subcutaneously). It should be injected into the stomach area, thigh, or outer upper arm. Continue reading

How is Arzerra administered and how long to work?

Arzerra (ofatumumab) was administered by an intravenous infusion. Arzerra has now been discontinued.

Continue reading

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.